BIS vs. XLV
Compare and contrast key facts about ProShares UltraShort Nasdaq Biotechnology (BIS) and Health Care Select Sector SPDR Fund (XLV).
BIS and XLV are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIS is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (-200%). It was launched on Apr 7, 2010. XLV is a passively managed fund by State Street that tracks the performance of the Health Care Select Sector. It was launched on Dec 16, 1998. Both BIS and XLV are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIS or XLV.
Key characteristics
| BIS | XLV | |
|---|---|---|
| YTD Return | 6.69% | 3.45% |
| 1Y Return | -1.48% | 6.92% |
| 3Y Return (Ann) | -2.38% | 6.69% |
| 5Y Return (Ann) | -22.52% | 11.22% |
| 10Y Return (Ann) | -25.22% | 11.10% |
| Sharpe Ratio | 0.03 | 0.61 |
| Daily Std Dev | 33.57% | 10.54% |
| Max Drawdown | -99.76% | -39.18% |
| Current Drawdown | -99.70% | -4.84% |
Correlation
The correlation between BIS and XLV is -0.73. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Performance
BIS vs. XLV - Performance Comparison
In the year-to-date period, BIS achieves a 6.69% return, which is significantly higher than XLV's 3.45% return. Over the past 10 years, BIS has underperformed XLV with an annualized return of -25.22%, while XLV has yielded a comparatively higher 11.10% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIS vs. XLV - Expense Ratio Comparison
BIS has a 0.95% expense ratio, which is higher than XLV's 0.12% expense ratio.
Risk-Adjusted Performance
BIS vs. XLV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares UltraShort Nasdaq Biotechnology (BIS) and Health Care Select Sector SPDR Fund (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIS vs. XLV - Dividend Comparison
BIS's dividend yield for the trailing twelve months is around 2.48%, more than XLV's 1.57% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIS ProShares UltraShort Nasdaq Biotechnology | 2.48% | 1.75% | 0.00% | 0.00% | 0.44% | 2.11% | 0.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XLV Health Care Select Sector SPDR Fund | 1.57% | 1.59% | 1.47% | 1.33% | 1.49% | 2.16% | 1.56% | 1.46% | 1.59% | 1.43% | 1.34% | 1.51% |
Drawdowns
BIS vs. XLV - Drawdown Comparison
The maximum BIS drawdown since its inception was -99.76%, which is greater than XLV's maximum drawdown of -39.18%. Use the drawdown chart below to compare losses from any high point for BIS and XLV. For additional features, visit the drawdowns tool.
Volatility
BIS vs. XLV - Volatility Comparison
ProShares UltraShort Nasdaq Biotechnology (BIS) has a higher volatility of 10.82% compared to Health Care Select Sector SPDR Fund (XLV) at 3.14%. This indicates that BIS's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.